• LAST PRICE
    80.9900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    77.8100/ 4
  • Ask / Lots
    78.0000/ 1
  • Open / Previous Close
    79.0000 / 80.9900
  • Day Range
    Low 78.5990
    High 81.3600
  • 52 Week Range
    Low 25.9800
    High 110.2500
  • Volume
    2,367,488
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract
    • 9 hours ago by MT Newswires
      Companies Mentioned: CYTK
      04:23 PM EST, 02/27/2024 (MT Newswires) -- Cytokinetics (CYTK) reported a Q4 net loss late Tuesday of $1.38 per diluted share, narrower than a loss of $1.45 a year earlier. Analysts polled by Capital IQ expected a loss of $0.99. Revenue for the quar...
    • 9 hours ago by MT Newswires
      Companies Mentioned: CYTK
      04:01 PM EST, 02/27/2024 (MT Newswires) -- ...
    • 9 hours ago by GlobeNewswire
      Companies Mentioned: CYTK
    • 9 hours ago by Dow Jones
      Companies Mentioned: CYTK
      revenues 1,000 -- 3,500 1,000 Realization of revenue participation right purchase agreement -- -- -- 87,000 Total revenues 1,672 1,957 7,530 94,588 --------- --------- --------- --------- Operating expenses: Research and development 84,976 75,018 330,123 240,813 General and administrative 44,114 53,969 173,612 177,977 Total operating expenses 129,090 128,987 503,735 418,790 --------- --------- --------- --------- Operating loss (127,418) (127,030) (496,205) (324,202) Interest expense (7,164) (7,057) (28,306) (19,414) Loss on settlement of debt -- -- -- (24,939) Non-cash interest expense on liabilities related to revenue participation right purchase agreements (9,900) (9,212) (29,362) (31,742) Interest and other income, net 7,586 5,919 27,629 11,342 --------- --------- --------- --------- Net loss before income taxes (136,896) (137,380) (526,244) (388,955) Income tax benefit -- -- -- -- Net loss $(136,896) $(137,380) $(526,244) $(388,955) ========= ========= ========= ========= Net loss per share -- basic and diluted $ (1.38) $ (1.45) $ (5.45) $ (4.33) ========= ========= ========= ========= Weighted-average shares in net loss per share -- basic and diluted 99,067 94,681 96,524 89,825 ========= ========= ========= =========
    • 9 hours ago by Dow Jones
      Companies Mentioned: CYTK
      revenues 1,000 -- 3,500 1,000 Realization of revenue participation right purchase agreement -- -- -- 87,000 Total revenues 1,672 1,957 7,530 94,588 --------- --------- --------- --------- Operating expenses: Research and development 84,976 75,018 330,123 240,813 General and administrative 44,114 53,969 173,612 177,977 Total operating expenses 129,090 128,987 503,735 418,790 --------- --------- --------- --------- Operating loss (127,418) (127,030) (496,205) (324,202) Interest expense (7,164) (7,057) (28,306) (19,414) Loss on settlement of debt -- -- -- (24,939) Non-cash interest expense on liabilities related to revenue participation right purchase agreements (9,900) (9,212) (29,362) (31,742) Interest and other income, net 7,586 5,919 27,629 11,342 --------- --------- --------- --------- Net loss before income taxes (136,896) (137,380) (526,244) (388,955) Income tax benefit -- -- -- -- Net loss $(136,896) $(137,380) $(526,244) $(388,955) ========= ========= ========= ========= Net loss per share -- basic and diluted $ (1.38) $ (1.45) $ (5.45) $ (4.33) ========= ========= ========= ========= Weighted-average shares in net loss per share -- basic and diluted 99,067 94,681 96,524 89,825 ========= ========= ========= =========

Peers Headlines